A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
Public ClinicalTrials.gov record NCT00920946. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients With Mile-to-Moderate Huntington Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if Dimebon is safe and effective for the treatment of cognitive impairment in Huntington disease.
Study identification
- NCT ID
- NCT00920946
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 403 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2009
- Primary completion
- Jun 30, 2011
- Completion
- Not listed
- Last update posted
- Oct 11, 2016
Started 2009
United States locations
- U.S. sites
- 24
- U.S. states
- 15
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Scottsdale | Arizona | 85259 | — |
| Not listed | Davis | California | 95616 | — |
| Not listed | Irvine | California | 92697 | — |
| Not listed | La Jolla | California | 92161 | — |
| Not listed | San Francisco | California | 94143 | — |
| Not listed | Gainsville | Florida | 32610 | — |
| Not listed | Miami | Florida | 33136 | — |
| Not listed | Boise | Idaho | 83702 | — |
| Not listed | Indianapolis | Indiana | 46202 | — |
| Not listed | Kansas City | Kansas | 66160 | — |
| Not listed | Wichita | Kansas | 67206 | — |
| Not listed | Charlestown | Massachusetts | 02129 | — |
| Not listed | Golden Valley | Minnesota | 55427 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | New York | New York | 10032 | — |
| Not listed | Rochester | New York | 14620 | — |
| Not listed | Durham | North Carolina | 27705 | — |
| Not listed | Winstom-Salem | North Carolina | 27157 | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Columbus | Ohio | 43210 | — |
| Not listed | Portland | Oregon | 97201 | — |
| Not listed | Philadelphia | Pennsylvania | 19107 | — |
| Not listed | Pittsburgh | Pennsylvania | 15213 | — |
| Not listed | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00920946, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 11, 2016 · Synced Sep 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00920946 live on ClinicalTrials.gov.